Both in Pharmaceuticals
Arvinas vs CytomX Therapeutics
Over the past year ARVN returned −27.1% and CTMX returned −44.5%; their daily moves had a correlation of 0.31.
ARVN −27.1% CTMX −44.5%Growth of $1, one year, split-adjusted
| Metric | ARVN | CTMX |
|---|---|---|
| Price | $7.09 | $2.18 |
| Market cap | $463.6M | $475.0M |
| Today | −5.72% | −2.24% |
| 1 month | −5.0% | −15.5% |
| 6 months | −33.2% | −46.6% |
| Year to date | −40.2% | −48.8% |
| 1 year | −30.1% | −38.9% |
| Revenue growth (YoY) | +1014.7% | −92.4% |
| Gross margin | 96.4% | 100.0% |
| Net margin | 67.8% | −1457.4% |
| P/E (TTM) | 49.8× | — |
| Price / sales | 1.5× | 26.0× |
| Net cash | $567.6M | $330.3M |
| Dividend yield | — | — |
| Volatility (60d) | 48.4% | 67.6% |
| Short % of float | 10.2% | 21.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).